Aeterna Zentaris (AEZS) Misses Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities rebound to close higher as surging Treasury yields recede
- Fed’s Jefferson sees no urgency for another rate increase
- Oil jumps 4% on reports China halts fuel exports, US troops head to Middle East
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Anthropic targets mid-November for public debut - report
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
UPDATE: Canaccord Genuity Upgrades AEterna Zentaris (AEZS) to Spec. Buy; Analyst Notes Removal of Dilution Overhang From Series B Warrants
November 9, 2015 6:42 AM EST(Updated - November 9, 2015 10:49 AM EST)
Canaccord Genuity upgraded Æterna Zentaris (NASDAQ: AEZS) from Hold to Spec. Buy with a price target of $0.10. Analyst Neil Maruoka said the agreement to exercise the majority of the Series B warrants substantially removes the single largest overhang for the stock. He also thinks Zoptrex pivotal data before the end of 2016 will major catalyst for the stock.
Maruoka explained, "Since Æterna Zentaris last reporting date, its stock price has continued to decline, losing ~66% of its value at the most recent closing price of US$0.057. We... More
